Non-Insulin Therapies for Diabetes Market Analysis and Forecast to 2027 By Recent Trends, Developments in Manufacturing Technology and Regional Growth Overview

Overview

Non-insulin treatments are most commonly utilized in individuals with type 2 diabetes, in whom the body either does not generate enough insulin or is unable to use the insulin it does produce efficiently. Non-insulin-based medications function through a variety of mechanisms to lower blood glucose levels and keep them stable for optimal glycemic control. Sulfonylureas enhance insulin secretion from pancreatic cells, Biguanides significantly raise glucose metabolism by the peripheral tissues while lowering hepatic glucose output, alpha glucosidase inhibitors delay sucrose digestion in the small intestine, and some medications reduce post-meal sugar by blocking certain enzymes.

Get PDF Brochure Here

Drivers

The global non-insulin therapies for diabetes market is projected to expand as the incidence rate and prevalence of diabetes rises. Non-insulin treatments are most commonly utilized in type 2 diabetes, which accounts for around 90% of all diabetes cases worldwide. As per the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, there were about 425 million diabetic people globally, with around 400 million having type II diabetes. According to a 2017 WHO study, diabetes is one of the top three non-communicable disease causes of mortality globally, with 114.4 million cases in China, 72.9 million cases in India, and 30.2 million cases in the U.S.

Diabetes has a large economic impact worldwide, which is anticipated to grow significantly over the next several years. As per a March 2018 study by the American Diabetes Association, the overall expenses of diagnosed diabetes increased to US$ 327 billion in 2017 from US$ 245 billion in 2012. As a result, the global non-insulin therapies for diabetes market is projected to expand in the coming years.

In addition, businesses are introducing innovative products and combination treatments to the market, which is impelling growth of the global non-insulin therapies for diabetes market. The Food and Drug Administration (FDA) authorized Novo Nordisk’s Ozempic (semiglutide), a once-week GLP-1 analogue that would improve patient compliance, in 2017. The FDA authorized ertugliflozin (Steglatro), a sodium-glucose co-transporter 2 (SGLT2) inhibitor developed collaboratively by Merck & Co. and Pfizer Inc., in December 2017, while the European Medicines Agency (EMA) cleared the same in January 2018.

Restraints

The global non-insulin therapies for diabetes market development is projected to be hampered by the high cost of newer classes of medications as compared to traditional drugs, particularly in places such as South Asia, where there is a substantial number of people suffering from type 2 diabetes. GLP-1 analogues cost about $492 for a 30-day course of treatment, whereas biguanides and sulfonylureas cost around $5-9 for a 30-day course of treatment.

Regional Analysis

Considering the largest diabetes expenditures in the U.S., North America is projected to drive growth in the global non-insulin therapies for diabetes market. As per the International Diabetes Federation (IDF), the U.S. saw about 17,100 new cases of diabetes in 2017.

Given the growing diabetes prevalence in China and India, which together have over 180 million diabetic patients, Asia Pacific is one of the most profitable regions. As per the American Diabetes Association (ADA), between 2000 and 2035, the incidence of type 2 diabetes in South Asia is expected to rise by more than 150 percent.

The newest category of medicines, such as GLP-1 analogues or SGLT2, is increasingly being targeted by major companies. Since 2013, SGLT 2 inhibitors have been authorized for use as a diabetic therapy. The majority of SGL2 inhibitors, including Dapagliflozin, Canagliflozin, and Empagliflozin, were introduced after 2013. Although, due to fierce competition in the industry, it may be difficult for one firm to get a bigger proportion of the global non-insulin therapies for diabetes market.

Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2042

Non-Insulin Therapies for Diabetes Market – Competitive Landscape

Key players functioning in the global prosthetic liners market consists of AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, and Takeda Pharmaceuticals.

Main points in Non-Insulin Therapies for Diabetes Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Non-Insulin Therapies for Diabetes Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Non-Insulin Therapies for Diabetes Industry Impact

Chapter 2 Global Non-Insulin Therapies for Diabetes Competition by Types, Applications, and Top Regions and Countries
2.1 Global Non-Insulin Therapies for Diabetes (Volume and Value) by Type
2.3 Global Non-Insulin Therapies for Diabetes (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Non-Insulin Therapies for Diabetes Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Non-Insulin Therapies for Diabetes Market Analysis
Chapter 6 East Asia Non-Insulin Therapies for Diabetes Market Analysis
Chapter 7 Europe Non-Insulin Therapies for Diabetes Market Analysis
Chapter 8 South Asia Non-Insulin Therapies for Diabetes Market Analysis
Chapter 9 Southeast Asia Non-Insulin Therapies for Diabetes Market Analysis
Chapter 10 Middle East Non-Insulin Therapies for Diabetes Market Analysis
Chapter 11 Africa Non-Insulin Therapies for Diabetes Market Analysis
Chapter 12 Oceania Non-Insulin Therapies for Diabetes Market Analysis
Chapter 13 South America Non-Insulin Therapies for Diabetes Market Analysis
Chapter 14 Company Profiles and Key Figures in Non-Insulin Therapies for Diabetes Business
Chapter 15 Global Non-Insulin Therapies for Diabetes Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com